Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Screenings of the substances from ISR's Immunolide platform have identified a new pharmaceutical lead candidate, ISR051, which has immune stimulating effects, apparently advantageous in the treatment of hepatitis B. ISR now plans to expand its research and development portfolio to encompass, apart from HIV, tuberculosis and cancer, also hepatitis B.
The hepatitis B virus (HBV) is one of the world's most ubiquitous diseases, where WHO estimates over two billion people have or have had the disease and 240 million are chronic bearers. Nearly 700,000 people die in this disease every year, and 25% of the chronically infected develop liver cirrhosis or hepatic cancer. Vaccinations against hepatitis B are successful, but there's no curative treatment.
"ISR's pediment is the comprehension of the activation and regulation of the immune system, where the company's investments to develop its own pharmaceutical platforms have come into fruition. The lead compound ISR051 will now be developed and brought forward to clinical drug trial for the indication hepatitis B. We're aware of the immense interest for this indication in Asia", comments Ola Winqvist, CEO ISR.
This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU's Market Abuse Regulation (MAR), and the Market Abuse Act. The information was sent in for publication through the above contact person on 4th October 2018; 08.48 AM.